LY900009

CAS No. 209984-68-9

LY900009( —— )

Catalog No. M23950 CAS No. 209984-68-9

LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 89 In Stock
5MG 73 In Stock
10MG 115 In Stock
25MG 207 In Stock
50MG 300 In Stock
100MG 434 In Stock
200MG 609 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LY900009
  • Note
    Research use only, not for human use.
  • Brief Description
    LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein.
  • Description
    LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    Gamma-secretase
  • Recptor
    γ secretase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    209984-68-9
  • Formula Weight
    409.49
  • Molecular Formula
    C23H27N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2C3=CC=CC=C3N(C1=O)C)NC(=O)[C@H](C(C)C)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer[J]. European Journal of Cancer, 2016, 56.
molnova catalog
related products
  • Jagged-1 188-204

    This peptide is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-αB activation.

  • Enoticumab

    Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody with anticancer activity that inhibits the growth of cancer cells.Enoticumab binds human Dll4 and disrupts Notch-mediated signaling.

  • Demcizumab

    Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.